KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Cash & Equivalents (2016 - 2025)

Resmed's Cash & Equivalents history spans 17 years, with the latest figure at $1.4 billion for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 171.5% year-over-year to $1.4 billion; the TTM value through Dec 2025 reached $1.4 billion, up 171.5%, while the annual FY2025 figure was $1.2 billion, 407.4% up from the prior year.
  • Cash & Equivalents reached $1.4 billion in Q4 2025 per RMD's latest filing, up from $1.4 billion in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $1.4 billion in Q4 2025 to a low of $194.5 million in Q4 2021.
  • Average Cash & Equivalents over 5 years is $458.8 million, with a median of $245.8 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: crashed 36.25% in 2021, then skyrocketed 407.4% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $194.5 million in 2021, then skyrocketed by 30.2% to $253.2 million in 2022, then decreased by 16.96% to $210.2 million in 2023, then surged by 148.25% to $521.9 million in 2024, then skyrocketed by 171.5% to $1.4 billion in 2025.
  • Per Business Quant, the three most recent readings for RMD's Cash & Equivalents are $1.4 billion (Q4 2025), $1.4 billion (Q3 2025), and $1.2 billion (Q2 2025).